The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2019

PART 4 U.K. Transitional Provision

4.—(1) For a period of six months beginning with [F1 IP completion day] the requirements of the provisions listed in paragraph (2) do not apply to—

(a) an import of tissues or cells into [F2 Great Britain] from an EEA state or Gibraltar;

(b) an export of tissues or cells from [F3 Great Britain] into an EEA state or Gibraltar,

provided that the Authority is satisfied that the import or, as the case may be, export meets the requirements of traceability and standards of quality and safety equivalent to those laid down in the Regulations.

(2) The provisions referred to in paragraph (1) are—

(a) regulation 11(4A) to (4C) of the Regulations.

(b) Schedule 2 to the Regulations.

(3) In this regulation—

(a) “the Regulations” means the Human Tissue (Quality and Safety for Human Application) Regulations 2007; and

(b) the terms “the Authority”, “cells”, “tissue” and “traceability” have the same meanings as they have in the Regulations.

Textual Amendments

F1 Words in reg. 4(1) substituted (31.12.2020 immediately before IP completion day) by The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1306), regs. 1, 26(a)

F2 Words in reg. 4(1)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1306), regs. 1, 26(b)

F3 Words in reg. 4(1)(b) substituted (31.12.2020 immediately before IP completion day) by The Human Tissue (Quality and Safety for Human Application) (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1306), regs. 1, 26(b)

Commencement Information

I1 Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1